Pfaller, M.A., Boyken, L., Hollis, R.J., et al. (2008) In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance. Journal of Clinical Microbiology, 46, 150-156.
https://doi.org/10.1128/JCM.01901-07

has been cited by the following article:

• TITLE: Optimizing the Dosage Regimen of Micafungin against Candida spp in HIV Positive Patients with EC Based on Mote Carlo Simulation

  AUTHORS: Ying Wang, Jingyi Zhao, Song Jiang, Yinhui Yao, Hainan Wen

  KEYWORDS: Monte Carlo Simulation, Micafungin, HIV Positive Patients, Esophageal Candidiasis

  JOURNAL NAME: Open Journal of Preventive Medicine, Vol.10 No.6, June 17, 2020

  ABSTRACT: The objective of our study was to explore the possibility of the antifungal efficacy of various micafungin dosage regimens against Candida spp in HIV positive patients with EC. According to pharmacokinetic/pharmacodynamics parameters of micafungin in HIV positive patients and MICs distribution of micafungin against Candida spp. in published studies, the dosage regimens of micafungin were 50, 100 and 150 mg QD iv. Monte Carlo Simulation analysed the probability of target attainment and cumulative fraction of response. The results showed that micafungin has good antifungal effect in treating HIV positive patients with EC when pathomycetes are Candida albicans, Candida glabrata or Candida tropicalis, in dosage at 100 mg QD and 150 mg QD.